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A concise assembly of the 1,3-benzodiazepine core from A3-coupling-derived propargylamines and
ortho-bromophenylisocyanates is described. The developed synthetic sequence involves the addition of
propargylamine to isocyanate followed by palladium-catalyzed intramolecular alkyne hydroarylation
that could be accomplished in a stepwise or one-pot manner.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Nitrogen-containing seven-membered heterocyclic systems
such as 3-benzazepine1 and 1,4-benzodiazepine2 constitute a core
structural elements of many natural and biologically active mole-
cules and therefore could be rightfully designated as privileged
structures (Fig. 1).3 Fenoldopam, a representative 3-benzazepine-
containing medication, is the ﬁrst selective peripheral dopamine
receptor agonist approved for clinical use for the treatment of se-
vere hypertension.4 Diazepam belongs to a large family of 1,4-
benzodiazepine-based psychoactive drugs whose mechanism of
action involves the enhancement of the inhibitory activity of the
gamma-aminobutyric acid (GABA) neurotransmitter at the GABAA
receptor, resulting in sedative, sleep-inducing, anxiolytic, alcohol
withdrawal, anticonvulsant, and muscle relaxant therapeutic
properties.5ivko), vsevolod@suda.edu.cn1,3-Benzodiazepine skeleton, which results from a small struc-
tural deviation from the above scaffolds (Fig. 1), has been relatively
less studied in terms of synthesis6 and potential biological and
therapeutic applications.7 Therefore, we set a goal to develop a
combinatorial route to provide a diversity-oriented entry to this
medium-ring-containing class of heterocycles.
Recently, others and we made substantial efforts on exploiting
A3-coupling-derived propargylamines in heterocyclic chemistry.8,9
Subjecting secondary propargylamines 1 to a palladium-catalyzed
intramolecular alkyne hydroarylation process, we were able to
attain a small set of 3-benzazepines 2 (Scheme 1).10,11 Using pri-
mary propargylamines 3, we have developed a series of protocols
that selectively convert in situ generated propargylureas 4 into
imidazol-2-ones 5,12,13 imidazolidin-2-ones 6,14 oxazolidin-2-
imines 7,15 and pyrimidin-2-ones 816 via silver- or gold-catalyzed
cycloisomerizations (Scheme 1).2. Results and discussion
Inspired by these processes, we envisaged that the 1,3-
benzodiazepine core 9 could be assembled by a palladium-
catalyzed intramolecular alkyne hydroarylation of propargylic
Fig. 1. Nitrogen-containing seven-membered heterocyclic systems.
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bromophenyl isocyanates 11 (Scheme 2). The proposed hydro-
arylation process involves an oxidative insertion of the Pd(0)-
catalyst into the arylbromide moiety of 10, followed by a tripleScheme 1. Synthesis of various heterocycles from th
Scheme 2. Strategy towardsbond carbopalladation and subsequent trapping of the resulting
vinyl-palladium species A with sodium formate as reducing agent.
The carbopalladation step is crucial for the whole process and al-
lows to control the ring size and the double bond geometry in the
forming 1,3-benzodiazepine product 9 (Scheme 2).17 The required
secondary propargylamines 3 are readily accessible from primary
amines 12, aldehydes 13 and terminal acetylenes 14 through a
CuBr-catalyzed A3-coupling protocol (Scheme 2).18
Reacting propargylamine 3a with ortho-bromophenyl isocya-
nate (11a) gave propargylurea 10a in 98% yield. In turn, this sub-
strate was selected to perform the optimization of the Pd-catalyzed
intramolecular alkyne hydroarylation that is also frequently
referred to as reductive Heck reaction (Table 1). Conducting this
transformation in DMF/H2O mixtures that previously proved to be
beneﬁcial for such processes delivered desired 1,3-benzodiazepine
9a albeit in low yield of maximum 38% (Table 1, entries 1e3). At the
same time, this was accompanied by the degradation of signiﬁcant
amounts of urea 10a back to the propargylamine 3a (Table 1, entries
1e3). Using DMF or iPrOH as solvent gave no or little of 3a, but the
yield of target 9a remained insufﬁcient (Table 1, entries 4e6),
despite some enhancement observed when reaction in DMF was
conducted in the presence of phase-transfer catalyst (Table 1, entry
5). To our delight, the yield of 9a was substantially improved bye A3-coupling-derived propargylamines 1 and 3.
1,3-benzodiazepines 9.
Table 1
Optimization of the Pd-catalyzed intramolecular alkyne hydroarylation (reductive Heck) step.a
Entry Catalyst Solvent Time, h Yield, %b
9a 3a
1 Pd(PPh3)4 DMF/H2O (3:1) 1 13 43
2 Pd(PPh3)2Cl2 DMF/H2O (3:1) 1 38 15
3 Pd(PPh3)2Cl2 DMF/H2O (9:1) 1 21 25
4 Pd(PPh3)2Cl2 DMF 1 36 e
5c Pd(PPh3)2Cl2 DMF 2 46 e
6 Pd(PPh3)2Cl2 iPrOH 4 34 9
7 Pd(PPh3)2Cl2 iPrOH/H2O (3:1) 4 62 26
8 Pd(PPh3)2Cl2 iPrOH/H2O (4:1) 4 57 14
9 Pd(PPh3)2Cl2 tBuOH/H2O (3:1) 4 55 18
10 3 mol% Pd(OAc)2/6 mol% PPh3 iPrOH/H2O (3:1) 4 54 15
11 Pd(PPh3)4 iPrOH/H2O (3:1) 4 28 38
12d 10 mol% Ni(cod)2/20 mol% P(nBu)3 THF 18 ee e
a The reactions were run at 110 C on 0.25 mmol scale in 2 mL of solvent with 1.5 equiv od sodium formate as reducing agent.
b The yields of 9a and 3a were determined by 1H NMR of the reaction mixture after work-up using 3,4,5-trimethoxybenzaldehyde as internal standard.
c The reaction was conducted in the presence of 1 equiv of tetra-butylammonium bromide (TBAB).
d The reaction was conducted at 100 C in 0.5 mL of THF with 1.2 equiv of triethylsilane as reducing agent.
e 65% of unreacted 10a was detected by 1H NMR analysis of reaction mixture after removal of nickel catalyst by ﬁltration through a short plug of silica gel. cod ¼ 1,5-
cyclooctadiene.
G. Wang et al. / Tetrahedron 73 (2017) 6372e63806374switching to iPrOH/H2O or tBuOH/H2O mixtures as the reaction
media, although the competing degradation of 10a into 3a could
not be completely suppressed (Table 1, entries 7e9). The best result
was obtained for the reaction with Pd(PPh3)2Cl2 as a catalyst and
iPrOH/H2O (3:1) as solvent producing 9a in 62% yield as was
determined by 1H NMR analysis of reaction mixture (Table 1, entry
7). Pd(OAc)2/PPh3 and Pd(PPh3)4 showed lower efﬁciency under the
same settings (Table 1, entries 10 and 11) while an attempt to utilizeScheme 3. Scope of the Pd-catalyzed intramolecular alkone of the literature protocols based on nickel catalysis19 was
completely unproductive (Table 1, entry 12).
Having effective conditions for the Pd-catalyzed alkyne hydro-
arylation step in hands, we moved to exploring the scope and
limitations of our strategy (Scheme 3). The required propargylurea
precursors 10 were obtained in high yields by reaction of prop-
argylamines 3 with ortho-bromophenyl isocyanates 11. The high
efﬁciency of this transformation motivated us to compare theyne hydroarylation leading to 1,3-benzodiazepine 9.
Fig. 2. X-ray crystallographic molecular structure of 1,3-benzodiazepine 9d, showing
thermal displacement ellipsoids at the 50% probability level.
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ﬁnal Pd-catalyzed alkyne hydroarylation process (Scheme 3). Using
propargylureas 10a-j bearing a (hetero)aromatic substituent on the
triple-bond and with no additional substituents on the isocyanate-
derived benzene ring (R4 ¼ H), the target 1,3-benzodiazepines 9a-j
were obtained in up to 62% and 52% for the stepwise and one-pot
approaches, respectively. The structure of the representative 1,3-
benzodiazepine 9d was conﬁrmed by X-ray crystallographic anal-
ysis (Fig. 2).20 Conducting the Pd-catalyzed intramolecular alkyne
hydroarylation with substrates 10k,l bearing alkyl group on the
triple-bond, led to an unclean reaction hampering the isolation of
desired products 9k,l. Thus, 1,3-benzodiazepines 9k,l were ob-
tained in a lower purity. The reactions of propargylureas 10m,n
derived from branched isocyanate 11b (R4 ¼ 4,6-diMe) delivered
1,3-benzodiazepines 9m,n in 64% and 69%, respectively (stepwise
approach).
With not too many ortho-bromophenyl isocyanates 11 being
commercially available, we turned our attention to the corres-
ponding ortho-bromophenyl carboxylic acids 15a,b. Reacting later
with diphenylphosphoryl azide (DPPA) in the presence of trie-
thylamine gave rise to the desired isocyanates 11c,d through a
Curtius rearrangement of initially formed acyl azides 16a,b.21 The
reactionmixtures containing either 11c or 11dwere directly treated
with propargylamine 3c allowing to attain propargylurea pre-
cursors 10o,p. Finally, Pd-catalyzed cyclization afforded 1,3-
benzodiazepines 9o,p featuring electron donating or electron
withdrawing R4 substituents (Scheme 4).
It is important to stress, that despite the moderate efﬁciency in
the Pd-catalyzed alkyne hydroarylation step, the overall synthetic
sequence towards 1,3-benzodiazepines 9 starting from amines 12,
aldehydes 13 and acetylenes 14 proved to be operationally simple
and robust. In fact, we have developed and implemented a practical
exercise for the fourth year undergraduate students, which is basedScheme 4. Extended scope of the Pd-catalyzed intramoleculaon this three-step methodology. The results obtained during 2016/
2017 academic year at Soochow University, China demonstrate that
the students from the intensive training class could satisfactorily
reproduce the procedures described in this study with a minimal
failure rate.22
In order to further extend the scope of our strategy and to
introduce an additional diversity point into target 1,3-benz-
odiazepine scaffold, we evaluated a base-promoted N-alkylation
reaction of 9 (Scheme 5a). Reacting 1,3-benzodiazepines 9 with
benzyl chlorides 17 or with methyl iodide (18) in the presence of
sodium hydride smoothly produced alkylated 1,3-benzodiazepines
19 in up to 96%. Another viable synthetic manipulation involved an
acid-promoted removal of the para-methoxybenzyl group23 from
the substrate 9f to afford 1,3-benzodiazepine 20 containing
two unprotected NH groups (Scheme 5b left). Interestingly, an
analogous transformation of 9e bearing phenyl group at the allylic
position was accompanied by a double-bond migration leading to
the formation of isomerized 1,3-benzodiazepine 21 (Scheme 5b
right).
3. Conclusion
In summary, we have developed a diversity-oriented strategy
towards 1,3-benzodiazepines that involves a one-pot or sequential
reaction of A3-coupling-derived propargylamines with ortho-bro-
mophenylisocyanates, followed by a palladium-catalyzed intra-
molecular alkyne hydroarylation. An additional N-alkylation step
further enriches the overall strategy allowing to construct a 1,3-
benzodiazepine core featuring ﬁve points of diversity.
4. Experimental
4.1. General information
All starting materials and solvents were purchased from com-
mercial sources and used as received. Melting points were
measured using INESA WRR apparatus. Infrared (FT-IR) spectra
were recorded neat on a Bruker Vertex 70. 1H (400 MHz) and 13C
(100MHz) NMR spectrawere recorded using a Bruker Avance III HD
instrument. The 1H and 13C chemical shifts are reported relative to
TMS using the residual CDCl3 signal as internal reference. HRMS
were performed on a Bruker micrOTF-Q III.
4.2. General procedure for the synthesis of secondary
propargylamines 3
Copper (I) bromide catalyst (17 mg, 0.12 mmol) was placed in a
screw cap vial followed by addition of dry toluene (1.0 mL), amine
12 (0.8 mmol), aldehyde 13 (1 mmol), and phenyl acetylene 14
(1.6 mmol). The resulting mixture was ﬂushed with argon, sealed
and stirred at 100 C for 5 h. Upon completion of this time, the
mixture was diluted with ethyl acetate and transferred to the round
bottom ﬂask. Then the silicagel was added and the mixture was
concentrated under reduced pressure. Column chromatography onr alkyne hydroarylation leading to 1,3-benzodiazepine 9.
Scheme 5. Base-promoted alkylation of 9 and PMB-deprotection of 9f and 9e.
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as eluent provided pure propargylamine 3.
4.3. General procedure for the synthesis of propargylureas 10a-n
Propargylamine 3 (0.7 mmol) was placed in a screw cap vial
followed by addition of dry DCM (2.8 mL) and ortho-bromophenyl
isocyanate 11 (1.05 mmol). The resulting mixture was sealed and
stirred at rt for 0.5 h. Upon completion of this time, themixturewas
diluted with ethyl acetate and transferred to the round bottom
ﬂask. Then the silicagel was added and the mixture was concen-
trated under reduced pressure. Column chromatography on silica
gel using petroleum ether-ethyl acetate (49:1 / 9:1) mixture as
eluent provided pure propargylurea 10.
4.4. General procedure for the synthesis of propargylureas 10o,p21c
2-Bromobenzoic acid 15 (2.5 mmol) was placed in a screw cap
vial followed by addition of dry dioxane (6 mL), diphenylphos-
phoryl azide (DPPA, 688 mg, 2.5 mmol) and triethylamine (273 mg,
2.7 mmol). The resulting mixturewas sealed and stirred at rt for 1 h
followed by heating at 100 C for another 2 h. Then propargylamine
3c (459 mg, 2 mmol) in dry dioxane (4 mL) was added and the
mixture was continued to stir at rt for 1 h. Upon completion of this
time, the mixture was diluted with ethyl acetate and transferred to
the round bottom ﬂask. Then the silicagel was added and the
mixture was concentrated under reduced pressure. Column chro-
matography on silica gel using petroleum ether-ethyl acetate (9:1
for 10o; 47:3 for 10p) mixture as eluent provided pure prop-
argylurea 10.
4.5. General procedure for the synthesis of 1,3-benzodiazepines 9
through the Pd-catalyzed intramolecular alkyne hydroarylation
Propargylurea 10 (0.5 mmol), bis(triphenylphosphine)palladiu-
m(II) dichloride (10.5 mg, 0.015 mmol) and sodium formate (51 mg,
0.75 mmol) were placed to the screw cap vial followed by addition
of isopropanol (3 mL) and water (1 mL). The resulting mixture was
ﬂushed with argon, sealed and stirred at 100 C for 4 h. Upon
completion of this time, the mixture was diluted with ethyl acetateand transferred to the round bottom ﬂask. Then the silicagel was
added and the mixture was concentrated under reduced pressure.
Column chromatography on silica gel using petroleum ether-ethyl
acetate (9:1 / 8:2 / 1:1) mixture as eluent provided 1,3-
benzodiazepine 9.
4.6. General procedure for the one-pot synthesis of 1,3-
benzodiazepines 9
Propargylamine 3 (0.5 mmol) was placed in a screw cap vial
followed by addition of dry DCM (2 mL) and ortho-bromophenyl
isocyanate 11 (0.75 mmol). The resulting mixture was sealed and
stirred at rt for 0.5 h. Upon completion of this time, the vial was
open and the DCM was evaporated under the ambient condition.
The crude propargylurea 10 was transferred to the next step. Bis(-
triphenylphosphine)palladium(II) dichloride (10.5mg, 0.015mmol)
and sodium formate (51 mg, 0.75 mmol) were added to the vial
with the crude urea 10 followed by addition of isopropanol (3 mL)
and water (1 mL). The resulting mixture was ﬂushed with argon,
sealed and stirred at 100 C for 4 h. Upon completion of
this time, the mixture was diluted with ethyl acetate and trans-
ferred to the round bottom ﬂask. Then the silicagel was
added and the mixture was concentrated under reduced pressure.
Column chromatography on silica gel using petroleum ether-ethyl




Yield: 61% (stepwise from 10a); beige solid; mp: 127e129 C; 1H
NMR (400MHz, CDCl3): d 7.76 (bs,1H), 7.44e7.33 (m, 4H), 7.27e7.12
(m, 6H), 7.03e6.94 (m, 2H), 6.91e6.82 (m, 3H), 4.87 (d, J ¼ 14.5 Hz,
1H), 4.49 (dd, J ¼ 8.8, 7.0 Hz, 1H), 3.70 (d, J ¼ 14.5 Hz, 1H), 1.51e1.21
(m, 2H), 1.10e0.78 (m, 2H), 0.57 (t, J ¼ 7.3 Hz, 3H); 13C NMR
(100 MHz, CDCl3): d 157.2, 139.3, 137.7, 137.6, 137.2, 129.6, 129.1,
128.94, 128.92, 128.5, 128.3, 128.0, 127.4, 127.2, 125.3, 121.7, 118.6,
54.5, 53.9, 33.7, 19.5, 13.8; IR (ATR, neat): n 3210, 3066, 3023, 2960,
2926, 2860, 1655, 1576, 1474, 1454, 1432, 1339, 1281, 1260, 1219,
830, 755, 721, 697 cm1; HRMS (ESI, [MþH]þ) for C26H27N2Oþ
calcd. 383.2118, found 383.2116.
G. Wang et al. / Tetrahedron 73 (2017) 6372e6380 63774.6.2. (Z)-5-Benzylidene-3-(4-methoxybenzyl)-4-propyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9b)
Yield: 51% (stepwise from 10b); white solid; mp: 220e222 C;
1H NMR (400 MHz, CDCl3): d 7.71 (bs, 1H), 7.45e7.32 (m, 4H),
7.26e7.16 (m, 3H), 7.03e6.92 (m, 2H), 6.91e6.74 (m, 3H), 6.68 (d,
J ¼ 8.5 Hz, 2H), 4.81 (d, J ¼ 14.4 Hz, 1H), 4.49 (t, J ¼ 7.8 Hz, 1H), 3.77
(s, 1H), 3.64 (d, J ¼ 14.4 Hz, 1H), 1.50e1.26 (m, 2H), 1.12e0.82 (m,
2H), 0.59 (t, J ¼ 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): d 159.0,
156.7, 139.2, 137.7, 136.9, 130.3, 129.8, 129.7, 129.2, 129.0, 128.6,
128.1, 127.3, 125.3, 121.9, 118.3, 113.7, 55.3, 54.1, 53.1, 33.7, 19.6, 13.9;
IR (ATR, neat): n 3325, 3210, 3071, 3022, 2960, 2926, 2853, 1655,
1614,1575,1511,1474,1436,1323,1305,1281,1233,1305,1281,1233,
1220, 1173, 1029, 831, 761, 754, 699, 688, 658 cm1; HRMS (ESI,
[MþNa]þ) for C27H28N2O2Naþ calcd.435.2043, found 435.2055.4.6.3. (Z)-5-Benzylidene-3-butyl-4-propyl-1,3,4,5-tetrahydro-2H-
benzo[d][1,3]diazepin-2-one (9c)
After column chromatography, product 9c was additionally
puriﬁed by washing with diethyl ether. Yield: 62% (stepwise from
10c), 52% (one-pot from 3c and 11a); white solid; mp: 243e245 C;
1H NMR (400 MHz, CDCl3): d 8.25 (bs, 1H), 7.45e7.35 (m, 3H),
7.34e7.17 (m, 4H), 7.01e6.94 (m, 1H), 6.94e6.87 (m, 2H), 4.57 (t,
J ¼ 7.9 Hz, 1H), 3.46e3.32 (m, 1H), 3.11e2.97 (m, 1H), 1.75e1.61 (m,
1H), 1.61e1.48 (m,1H), 1.45e1.20 (m, 3H), 1.20e1.01 (m, 4H), 0.84 (t,
J ¼ 7.3 Hz, 3H), 0.71 (t, J ¼ 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d 156.1, 139.6, 137.5, 137.1, 129.7, 129.0, 128.9, 128.6, 128.3, 127.3,
125.3,121.6,118.2, 55.7, 51.2, 34.3, 30.3, 20.0,19.9,14.2,13.7; IR (ATR,
neat): n 3218, 3116, 3077, 3020, 2958, 2933, 2872, 1656, 1577, 1476,
1462, 1434, 1361, 1302, 1219, 1074, 817, 749, 699, 661 cm1; HRMS
(ESI, [MþH]þ) for C23H29N2O calcd. 349.2274, found 349.2256.4.6.4. (Z)-5-Benzylidene-4-isobutyl-3-(4-methoxybenzyl)-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9d)
After column chromatography, product 9d was additionally
puriﬁed by washing with diethyl ether. Yield: 42% (stepwise from
10d), 40% (one-pot from 3d and 11a); white solid; mp: 223e226 C;
1H NMR (400 MHz, CDCl3): d 8.69 (bs, 1H), 7.48e7.32 (m, 4H),
7.25e7.16 (m, 3H), 7.05e6.90 (m, 3H), 6.84 (d, J ¼ 8.4 Hz, 2H), 6.70
(d, J ¼ 8.4 Hz, 2H), 4.89 (d, J ¼ 14.4 Hz, 1H), 4.52 (t, J ¼ 7.0 Hz, 1H),
3.78 (s, 3H), 3.74 (d, J ¼ 14.5 Hz, 1H), 1.38e1.19 (m, 3H), 0.58 (d,
J ¼ 5.8 Hz, 3H), 0.49 (d, J ¼ 5.7 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d 159.0, 157.1, 139.7, 137.7, 137.1, 130.4, 129.8, 129.6, 129.2, 128.9,
128.5, 127.8, 127.2, 125.5, 121.8, 118.5, 113.7, 55.4, 53.1, 52.8, 40.8,
24.9, 22.7, 22.6; IR (ATR, neat): n 3210, 3071, 3022, 2960, 2902,1655,
1615, 1576, 1510, 1475, 1435, 1323, 1238, 1218, 1172, 1030, 834, 766,
755, 698, 659 cm1; HRMS (ESI, [MþNa]þ) for C28H30N2O2Naþ
calcd. 449.2199, found 449.2197.4.6.5. (Z)-5-Benzylidene-3-(4-methoxybenzyl)-4-phenyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9e)
After column chromatography, product 9e was additionally
puriﬁed by washing with diethyl ether. Yield: 39% (stepwise from
10e), 38% (one-pot from 3e and 11a); beige solid; mp: 246e248 C;
1H NMR (400 MHz, CDCl3): d 7.58e7.47 (m, 2H), 7.36e7.28 (m, 3H),
7.26e7.17 (m, 3H), 7.15e7.06 (m, 4H), 7.05e6.99 (m, 2H), 6.98e6.90
(m,1H), 6.80 (d, J¼ 8.5 Hz, 2H), 6.68e6.58 (m, 3H), 5.87 (s, 1H), 4.70
(d, J ¼ 14.4 Hz, 1H), 4.01 (d, J ¼ 14.4 Hz, 1H), 3.74 (s, 3H); 13C NMR
(100 MHz, CDCl3): d 159.1, 157.5, 138.5, 137.4, 137.2, 136.4, 130.6,
129.7, 129.2, 129.0, 128.84, 128.82, 128.80, 128.2, 127.5, 127.0, 126.1,
125.8, 122.0, 118.8, 113.8, 57.53, 55.26, 53.00; IR (ATR, neat): n 3212,
3077, 3026, 2832,1661,1577,1510,1472,1436,1302,1237,1218,1174,
1028, 824, 766, 750, 737, 698, 655 cm1; HRMS (ESI, [MþNa]þ) for
C30H26N2O2Naþ calcd. 469.1886, found 469.1878.4.6.6. (Z)-4-Benzyl-5-benzylidene-3-(4-methoxybenzyl)-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9f)
After column chromatography, product 9f was additionally pu-
riﬁed by washing with diethyl ether. Yield: 50% (stepwise from
10f); white solid; mp: 212e214 C; 1H NMR (400 MHz, CDCl3):
d 7.99e7.78 (m,1H), 7.43e7.36 (m,1H), 7.33e7.26 (m, 2H), 7.26e7.19
(m, 2H), 7.19e7.11 (m, 3H), 7.10e7.02 (m, 1H), 7.00e6.93 (m, 1H),
6.89 (s, 1H), 6.78e6.68 (m, 4H), 6.61e6.54 (m, 2H), 6.54e6.46 (m,
2H), 4.91 (d, J ¼ 14.3 Hz, 1H), 4.55 (dd, J ¼ 10.6, 4.4 Hz, 1H), 3.81 (s,
3H), 3.42 (d, J ¼ 14.3 Hz, 1H), 2.86 (dd, J ¼ 12.8, 10.8 Hz, 1H), 2.44
(dd, J ¼ 13.0, 4.4 Hz, 1H); 13C NMR (100 MHz, CDCl3): d 159.2, 156.7,
138.0, 137.3, 137.0, 130.5, 130.1, 129.6, 129.5, 129.2, 129.0, 128.7,
128.4, 128.3, 127.1, 126.7, 125.2, 122.1, 118.6, 113.8, 55.7, 55.4, 52.7,
38.5; IR (ATR, neat): n 3219, 3079, 2961, 2923, 2851, 1656, 1606,
1577, 1509, 1462, 1438, 1352, 1297, 1236, 1221, 1176, 1031, 831, 765,
758, 746, 701 cm1; HRMS (ESI, [MþNa]þ) for C31H28N2O2Naþ
calcd. 483.2043, found 483.2034.
4.6.7. (Z)-3-Benzyl-5-(4-ﬂuorobenzylidene)-4-isobutyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9g)
Yield: 53% (stepwise from 10g), 40% (one-pot from 3g and 11a);
beige solid; mp: 208e211 C; 1H NMR (400 MHz, CDCl3): d 7.65 (bs,
1H), 7.38 (dd, J ¼ 7.8, 1.2 Hz, 1H), 7.26e7.15 (m, 4H), 7.11e6.96 (m,
5H), 6.96e6.91 (m, 2H), 6.86 (s, 1H), 6.84 (dd, J ¼ 8.1, 0.6 Hz, 1H),
4.49e4.40 (m, 1H), 4.44 (t, J ¼ 7.3 Hz, 1H), 3.97 (d, J ¼ 14.6 Hz, 1H),
1.36e1.21 (m, 3H), 0.56 (d, J ¼ 6.1 Hz, 3H), 0.50 (d, J ¼ 6.0 Hz, 3H);
13C NMR (100 MHz, CDCl3): d 162.0 (d, J ¼ 247.0 Hz), 157, 139.8,
137.6, 137.0, 133.5 (d, J ¼ 3.4 Hz), 130.7 (d, J ¼ 7.9 Hz), 129.6, 129.1,
128.9, 128.4, 127.6, 127.0, 125.4, 121.9, 118.5 (d, J ¼ 1.3 Hz), 115.46 (d,
J ¼ 21.4 Hz), 54.0, 53.4, 40.9, 24.9, 22.7, 22.6; IR (ATR, neat): n 3213,
3068, 2952, 2923, 2868, 1657, 1579, 1504, 1473, 1454, 1431, 1329,
1286, 1218, 1155, 832, 757, 745, 730, 700, 657, 618 cm1; HRMS (ESI,
[MþNa]þ) for C27H27FN2ONaþ calcd. 437.2000, found 437.2007.
4.6.8. (Z)-4-((3-Butyl-4-isobutyl-2-oxo-1,2,3,4-tetrahydro-5H-
benzo[d][1,3]diazepin-5-ylidene)methyl)benzonitrile (9h)
Yield: 62% (stepwise from 10h), 47% (one-pot from 3i and 11a);
beige solid; mp: 236e238 C; 1H NMR (400MHz, CDCl3): d 8.54 (bs,
1H), 7.71 (d, J ¼ 7.9 Hz, 2H), 7.42e7.32 (m, 3H), 7.29e7.20 (m, 1H),
7.04e6.91 (m, 2H), 6.86 (s,1H), 4.50 (t, J¼ 7.3 Hz,1H), 3.52e3.37 (m,
1H), 3.11e2.97 (m, 1H), 1.72e1.50 (m, 2H), 1.44e1.31 (m, 1H),
1.23e1.04 (m, 4H), 0.91e0.79 (m, 6H), 0.75 (t, J ¼ 6.9 Hz, 3H); 13C
NMR (100 MHz, CDCl3): d 156.0, 142.4, 142.2, 137.2, 132.4, 129.7,
129.61, 129.55, 125.7, 124.6, 121.8, 118.7, 118.5, 111.0, 54.4, 51.5, 41.2,
30.4, 25.1, 23.1, 22.9, 20.0, 13.8; IR (ATR, neat): n 3198, 3056, 2955,
2933, 2866, 2223, 1653, 1603, 1580, 1500, 1486, 1474, 1436, 1362,
1339, 1308, 1228, 876, 832, 781, 746, 662 cm1; HRMS (ESI,
[MþH]þ) for C25H30N3O calcd. 388.2383, found 388.2364.
4.6.9. (Z)-3-Benzyl-4-isobutyl-5-(4-(triﬂuoromethyl)benzylidene)-
1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9i)
After column chromatography, product 9i was additionally pu-
riﬁed by washing with diethyl ether. Yield: 50% (stepwise from
10i); white solid; mp: 232e235 C; 1H NMR (400 MHz, CDCl3):
d 7.76e7.51 (m, 3H), 7.44e7.36 (m, 1H), 7.31e7.09 (m, 6H),
7.05e6.97 (m, 1H), 6.90 (s, 1H), 6.89e6.77 (m, 3H), 4.71 (d,
J ¼ 14.7 Hz, 1H), 4.42 (t, J ¼ 7.3 Hz, 1H), 3.97 (d, J ¼ 14.7 Hz, 1H),
1.48e1.22 (m, 3H), 0.60 (d, J ¼ 6.2 Hz, 3H), 0.51 (d, J ¼ 6.1 Hz, 3H);
13C NMR (100 MHz, CDCl3): d 157.0, 141.2, 141.0, 137.2, 137.1, 129.7,
129.5, 129.3 (q, J ¼ 32.5 Hz), 128.8, 128.5, 127.7, 126.3, 125.5 (q,
J¼ 3.7 Hz),125.0,124.3 (q, J¼ 271.9 Hz),122.0,118.6, 53.9, 53.1, 40.8,
25.0, 22.8, 22.6; IR (ATR, neat): n 3327, 3205, 3112, 3068, 2966, 2957,
2936, 2902, 2872, 1655, 1580, 1508, 1472, 1456, 1436, 1361, 1321,
1226, 1160, 1107, 1067, 1017, 884, 875, 831, 818, 751, 731, 701,
668 cm1; HRMS (ESI, [MþNa]þ) for C28H27F3N2ONaþ calcd.




Yield: 36% (stepwise from 10j); beige solid; mp: 206e208 C; 1H
NMR (400MHz, CDCl3): d 7.53 (bs, 1H), 7.41e7.32 (m, 2H), 7.26e7.18
(m, 1H), 7.03e6.89 (m, 5H), 6.83e6.79 (m, 1H), 6.78 (s, 1H), 6.74 (d,
J¼ 8.5 Hz, 2H), 4.76 (d, J¼ 14.5 Hz, 1H), 4.61 (dd, J¼ 8.7, 7.0 Hz, 1H),
3.87 (d, J ¼ 14.5 Hz, 1H), 3.79 (s, 3H), 1.51e1.32 (m, 2H), 1.13e0.84
(m, 2H), 0.62 (t, J ¼ 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): d 159.0,
157.0, 139.2, 138.2, 136.9, 130.1, 129.8, 129.6, 128.97, 128.95, 125.8,
125.3, 123.2, 122.4, 121.9, 118.5, 113.8, 55.3, 54.7, 53.4, 33.7, 19.6,
13.9; IR (ATR, neat): n 3322, 3220, 3114, 3079, 2990, 2968, 2936,
1656,1606,1577,1509,1462,1437,1352,1297,1236,1221,1176,1031,
831, 765, 758, 746, 702 cm1; HRMS (ESI, [MþNa]þ) for
C25H26N2O2SNaþ calcd. 441.1607, found 441.1597.
4.6.11. (Z)-3-(4-Methoxybenzyl)-5-pentylidene-4-propyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9k)
The isolated product was contaminated with unidentiﬁed im-
purities. Yield: 53% (67% purity, stepwise from 10k); washing with
diethyl ether can improve the purity but leads to signiﬁcant loses of
9k; yield after wash: 32% (78% purity); white solid; mp:
185e188 C; 1H NMR (400 MHz, CDCl3): d 7.75 (bs, 1H), 7.30 (d,
J¼ 8.5 Hz, 2H), 7.20e7.10 (m, 2H), 6.94e6.82 (m, 3H), 6.81e6.75 (m,
1H), 5.68 (t, J ¼ 7.3 Hz, 1H), 4.89 (d, J ¼ 14.8 Hz, 1H), 4.48 (d,
J ¼ 14.8 Hz, 1H), 4.24 (dd, J ¼ 8.9, 6.8 Hz, 1H), 3.80 (s, 3H), 1.91e1.77
(m, 1H), 1.70e1.59 (m, 1H), 1.47e1.36 (m, 2H), 1.29e1.17 (m, 4H),
1.06e0.92 (m, 2H), 0.90e0.83 (m, 3H), 0.68 (t, J ¼ 7.3 Hz, 3H); 13C
NMR (100 MHz, CDCl3): d 159.2, 156.1, 136.6, 136.1, 131.5, 130.2,
129.8, 129.4, 128.3, 126.6, 121.9, 117.8, 114.1, 55.4, 54.6, 53.3, 34.0,
32.1, 27.8, 22.6, 19.4, 14.1, 13.7; IR (ATR, neat): n 3198, 3058, 2962,
2932, 2861, 1653, 1581, 1512, 1461, 1434, 1336, 1249, 1226, 1176,
1036, 853, 830, 760, 732, 689 cm1; HRMS (ESI, [MþNa]þ) for
C25H32N2O2Naþ calcd. 415.2356, found 415.2348.
4.6.12. (Z)-5-Butylidene-3-(4-methoxybenzyl)-4-propyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9l)
The isolated product was contaminated with unidentiﬁed im-
purities. Yield: 46% (60% purity, stepwise from 10l); washing with
diethyl ether can improve the purity but leads to signiﬁcant loses of
9l; yield after wash: 25% (78% purity); beige solid; mp: 163e165 C;
1H NMR (400 MHz, CDCl3): d 8.16 (bs, 1H), 7.32 (d, J ¼ 8.4 Hz, 2H),
7.21e7.10 (m, 2H), 6.94e6.81 (m, 4H), 5.68 (t, J¼ 7.2 Hz,1H), 4.91 (d,
J¼ 14.8 Hz,1H), 4.50 (d, J¼ 14.8 Hz,1H), 4.24 (dd, J¼ 9.1, 6.5 Hz,1H),
3.80 (s, 3H),1.87e1.75 (m,1H),1.70e1.58 (m,1H),1.47e1.36 (m, 2H),
1.36e1.23 (m, 2H), 1.05e0.94 (m, 2H), 0.84 (t, J¼ 7.3 Hz, 3H), 0.68 (t,
J ¼ 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): d 159.2, 156.3, 136.8,
136.4, 131.2, 130.3, 129.9, 129.2, 128.3, 126.6, 121.7, 118.0, 114.1, 55.4,
54.6, 53.3, 34.0, 30.1, 23.1, 19.3, 14.0, 13.7; IR (ATR, neat): n 3200,
3062, 2957, 2930, 2859, 1654, 1613, 1581, 1512, 1487, 1462, 1435,
1334, 1309, 1248, 1228, 1175, 1037, 853, 828, 762, 734, 689 cm1;




Yield: 64% (stepwise from 10m), 48% (one-pot from 3h and 11b);
beige solid; mp: 168e170 C; 1H NMR (400 MHz, CDCl3):
d 7.24e7.15 (m, 2H), 7.13e7.04 (m, 2H), 7.02 (s, 1H), 6.96 (s, 1H), 6.80
(s, 1H), 6.63 (bs, 1H), 4.50 (t, J ¼ 7.2 Hz, 1H), 3.48e3.33 (m, 1H),
3.09e2.96 (m, 1H), 2.29 (s, 3H), 2.27 (s, 3H), 1.61e1.47 (m, 2H),
1.38e1.02 (m, 5H), 0.86e0.78 (m, 6H), 0.73 (t, J ¼ 7.1 Hz, 3H); 13C
NMR (100 MHz, CDCl3): d 162.0 (d, J ¼ 247.2 Hz), 155.3, 140.6, 133.5(d, J ¼ 3.5 Hz), 132.7, 131.7, 130.6, 130.5 (d, J ¼ 7.9 Hz), 128.4, 127.3,
125.7, 123.3, 115.5 (d, J ¼ 21.5 Hz), 54.4, 51.4, 41.7, 30.4, 25.0, 22.91,
22.90, 20.5, 20.0, 18.5, 13.7; IR (ATR, neat): n 3225, 2959, 2927, 2870,
1641,1505,1465,1430,1317,1220, 863, 836, 821, 781, 744, 612 cm1;





Yield: 69% (stepwise from 10n); beige solid; mp: 147e148 C; 1H
NMR (400 MHz, CDCl3): d 7.56 (d, J¼ 8.1 Hz, 2H), 7.23e7.10 (m, 5H),
7.06 (s, 1H), 7.01 (s, 1H), 6.91e6.83 (m, 3H), 6.78 (s, 1H), 4.67 (d,
J¼ 14.6 Hz, 1H), 4.41 (t, J¼ 7.2 Hz, 1H), 4.07 (d, J¼ 14.6 Hz, 1H), 2.35
(s, 3H), 2.30 (s, 3H), 1.42e1.19 (m, 3H), 0.60 (d, J ¼ 6.1 Hz, 3H), 0.54
(d, J ¼ 6.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): d 156.2, 141.3, 141.2,
137.2, 132.7, 132.1, 131.0, 129.3, 129.2 (d, J ¼ 32.6 Hz), 128.8, 128.5,
128.4,127.6,126.9,125.5,125.4 (q, J¼ 3.7 Hz),124.3 (d, J¼ 272.0 Hz),
123.7, 53.7, 53.2, 41.0, 24.9, 22.6, 22.6, 20.5, 18.5; IR (ATR, neat): n
3306, 3240, 2959, 2926, 2869, 1637, 1455, 1322 1292, 1163, 1125,
1103, 1066, 1017, 907, 862, 841, 760, 734, 714, 700 cm1; HRMS (ESI,
[MþNa]þ) for C30H31F3N2ONaþ calcd. 515.2281, found 515.2280.
4.6.15. (Z)-5-Benzylidene-3-butyl-7,8-dimethoxy-4-propyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9o)
Yield: 64% (stepwise from 10o); brown solid; mp: 183e184 C;
1H NMR (400 MHz, DMSO-d6): d 8.76 (bs, 1H), 7.46e7.38 (m, 2H),
7.34e7.24 (m, 3H), 6.90 (s, 2H), 6.83 (s, 1H), 4.52 (t, J ¼ 7.8 Hz, 1H),
3.75 (s, 3H), 3.72 (s, 3H), 3.35e3.24 (m, 1H), 2.85e2.74 (m, 1H),
1.72e1.58 (m, 1H), 1.57e1.43 (m, 1H), 1.41e1.17 (m, 2H), 1.02e0.87
(m, 4H), 0.82 (t, J ¼ 7.3 Hz, 3H), 0.61 (t, J ¼ 7.0 Hz, 3H); 13C NMR
(100 MHz, DMSO-d6) d 155.2, 149.4, 143.5, 138.5, 137.4, 131.2, 128.7,
128.4, 126.9, 125.3, 115.8, 112.0, 102.3, 55.8, 55.3, 54.4, 49.8, 33.5,
29.6, 19.27, 19.25, 14.0, 13.4; IR (ATR, neat): n 3342, 3212, 3090,
2950, 2929, 2857, 1664, 1444, 1251, 861, 697 cm1; HRMS (ESI,
[MþH]þ) for C25H33N2O3þ calcd. 409.2486, found 409.2478.
4.6.16. (Z)-5-Benzylidene-3-butyl-7-ﬂuoro-4-propyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9p)
Yield: 57% (stepwise from 10p); beige solid; mp: 187e188 C; 1H
NMR (400 MHz, DMSO-d6): d 9.08 (s, 1H), 7.48e7.40 (m, 2H),
7.37e7.27 (m, 3H), 7.23 (dd, J ¼ 10.1, 2.7 Hz, 1H), 7.18e7.04 (m, 2H),
6.99 (s,1H), 4.52 (t, J¼ 7.8 Hz,1H), 3.33e3.21 (m,1H), 2.92e2.79 (m,
1H), 1.69e1.53 (m, 1H), 1.53e1.39 (m, 1H), 1.38e1.12 (m, 2H),
1.04e0.86 (m, 4H), 0.79 (t, J¼ 7.3 Hz, 3H), 0.61 (t, J¼ 6.9 Hz, 3H); 13C
NMR (100 MHz, DMSO-d6) d 156.7 (d, J ¼ 237.0 Hz), 154.7, 137.9 (d,
J ¼ 1.4 Hz), 136.8, 134.0 (d, J ¼ 1.9 Hz), 128.7, 128.5, 127.3, 125.8 (d,
J ¼ 7.3 Hz), 119.5 (d, J ¼ 8.1 Hz), 115.8 (d, J ¼ 22.7 Hz), 114.8 (d,
J ¼ 22.9 Hz), 54.2, 49.8, 33.5, 29.6, 19.3, 19.2, 13.9, 13.4; IR (ATR,
neat): n 3334, 3221, 3102, 3065, 2957, 2931, 2872, 1660, 1475, 1222,
1189, 862, 828, 763, 700 cm1; HRMS (ESI, [MþH]þ) for
C23H28FN2Oþ calcd. 367.2180, found 367.2167.
4.7. General procedure for the synthesis of 1,3-benzodiazepines 19
by base-promoted alkylation of 9
1,3-Benzodiazepine 9 (0.3 mmol) was placed in a screw cap vial
followed by addition of dry THF (1 mL), sodium hydride (19.2 mg,
60% dispersion in mineral oil, 0.48 mmol) and benzyl chloride 17
(0.6 mmol) or methyl iodide (18, 85 mg, 0.6 mmol). The resulting
mixture was sealed and stirred at 60 C for 3 h. Upon completion of
this time, the mixture was diluted with ethyl acetate and trans-
ferred to the round bottom ﬂask. Then the silicagel was added and
the mixture was concentrated under reduced pressure. Column
chromatography on silica gel using petroleum ether-ethyl acetate





Yield: 93%; white solid; mp: 141e143 C; 1H NMR (400 MHz,
CDCl3): d 7.34e7.26 (m, 3H), 7.26e7.08 (m, 11H), 7.00e6.94 (m, 2H),
6.79 (d, J ¼ 8.6 Hz, 2H), 6.70 (s, 1H), 5.18 (d, J ¼ 15.4 Hz, 1H), 4.96 (d,
J¼ 15.4 Hz, 1H), 4.60e4.49 (m, 2H), 4.27 (d, J¼ 14.6 Hz, 1H), 3.82 (s,
3H),1.65e1.54 (m,1H),1.43e1.30 (m,1H),1.18e1.06 (m,1H), 0.59 (d,
J ¼ 6.6 Hz, 3H), 0.42 (d, J ¼ 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d 159.3, 159.0, 141.7, 139.2, 138.8, 136.7, 134.7, 130.5, 130.3, 130.1,
128.6, 128.6, 128.5, 128.3, 127.7, 127.1, 126.8, 124.5, 121.7, 113.9, 58.6,
55.4, 55.1, 51.7, 42.1, 24.6, 23.1, 22.0; IR (ATR, neat): n 3029, 2954,
2931, 2865, 1615, 1509, 1454, 1413, 1242, 1200, 1174, 1031, 770, 759,




Yield: 84%; white solid; mp: 144e147 C; 1H NMR (400 MHz,
CDCl3): d 7.30e7.17 (m, 5H), 7.13e7.05 (m, 5H), 7.05e6.94 (m, 5H),
6.85e6.78 (m, 2H), 6.74 (d, J ¼ 8.6 Hz, 2H), 5.71 (s, 1H), 4.28 (d,
J ¼ 14.3 Hz, 1H), 4.17 (d, J ¼ 14.3 Hz, 1H), 3.79 (s, 3H), 3.05 (s, 3H);
13C NMR (100 MHz, CDCl3): d 159.6, 159.1, 141.6, 140.0, 136.7, 136.6,
131.0, 130.8, 129.4, 128.84, 128.75, 128.6, 128.4, 128.2, 127.3, 127.0,
125.8,123.4, 119.8,113.8, 61.2, 55.3, 51.0, 37.8; IR (ATR, neat): n 2954,
2922, 2853, 1649, 1607, 1508, 1493, 1458, 1446, 1299, 1258, 1235,
1172, 1098, 1033, 851, 765, 749, 737, 725, 703, 609 cm1; HRMS (ESI,
[MþH]þ) for C31H29N2O2þ calcd. 461.2224, found 461.2231.
4.7.3. (Z)-5-Benzylidene-3-butyl-1-methyl-4-propyl-1,3,4,5-
tetrahydro-2H-benzo[d][1,3]diazepin-2-one (19c)
Yield: 89%; yellowish oil; 1H NMR (400 MHz, CDCl3): d 7.51 (dd,
J ¼ 7.7, 1.3 Hz, 1H), 7.43e7.35 (m, 2H), 7.35e7.25 (m, 4H), 7.15e7.03
(m, 2H), 6.92 (s, 1H), 4.49 (t, J ¼ 7.6 Hz, 1H), 3.31 (s, 3H), 3.20e3.07
(m, 2H), 1.88e1.73 (m, 1H), 1.47e1.18 (m, 5H), 1.18e1.04 (m, 2H),
0.79 (t, J ¼ 7.2 Hz, 3H), 0.76 (t, J ¼ 7.3 Hz, 3H); 13C NMR (100 MHz,
CDCl3): d 159.2,141.5,139.3,137.4,130.4,128.8,128.7,128.52,128.45,
127.9, 127.2, 122.9, 119.1, 58.9, 50.4, 38.0, 34.9, 30.2, 20.1, 19.5, 14.0,
13.8; IR (ATR, neat): n 2957, 2928, 2871,1649,1596,1459,1447,1300,
1233, 1118, 1096, 1033, 753, 700 cm1; HRMS (ESI, [MþH]þ) for
C24H31N2Oþ calcd. 363.2431, found 363.2443.
4.7.4. (Z)-5-Benzylidene-3-butyl-1-(3-chlorobenzyl)-4-propyl-
1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (19d)
Yield: 95%; yellowish oil; 1H NMR (400MHz, CDCl3): d 7.42e7.33
(m, 2H), 7.33e7.19 (m, 6H), 7.17e7.03 (m, 5H), 6.78 (s, 1H), 5.11 (d,
J ¼ 15.6 Hz, 1H), 4.91 (d, J ¼ 15.6 Hz, 1H), 4.41 (dd, J ¼ 8.6, 5.2 Hz,
1H), 3.34e3.20 (m, 1H), 3.19e3.05 (m, 1H), 1.71e1.56 (m, 1H),
1.52e1.35 (m, 2H), 1.25e0.94 (m, 5H), 0.81 (t, J¼ 7.3 Hz, 3H), 0.68 (t,
J ¼ 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): d 158.1, 141.5, 141.2,
139.2, 136.7, 134.6, 134.2, 130.7, 129.6, 128.8, 128.61, 128.59, 128.4,
127.46, 127.45, 126.9, 125.6, 124.5, 121.4, 62.1, 54.7, 50.4, 35.8, 30.5,
20.3, 19.0, 14.0, 13.9; IR (ATR, neat): n 2957, 2930, 2871, 1626, 1596,
1576, 1455, 1355, 1286, 1241, 1210, 1077, 760, 699, 683 cm1; HRMS
(ESI, [MþH]þ) for C30H34ClN2Oþ calcd. 473.2354, found 473.2362.
4.7.5. (Z)-3-Butyl-5-(4-ﬂuorobenzylidene)-4-isobutyl-1,7,9-
trimethyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (19e)
Yield: 96%; white solid; mp: 131e133 C; 1H NMR (400 MHz,
CDCl3): d 7.26e7.19 (m, 2H), 7.08e6.96 (m, 3H), 6.85 (s, 1H), 6.73 (s,
1H), 4.21 (dd, J ¼ 10.9, 2.5 Hz, 1H), 3.54e3.39 (m, 1H), 3.12 (s, 3H),
2.87e2.70 (m, 1H), 2.33 (s, 3H), 2.25 (s, 3H), 1.59e1.42 (m, 2H),1.40e1.04 (m, 4H), 0.98e0.82 (m, 4H), 0.69 (d, J ¼ 6.7 Hz, 3H), 0.39
(d, J ¼ 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): d 162.1 (d,
J ¼ 246.9 Hz), 161.0, 139.4, 138.8, 136.8, 135.7, 132.6, 132.5 (d,
J ¼ 3.4 Hz), 131.5, 130.5 (d, J ¼ 8.0 Hz), 129.4, 125.5115.51 (d,
J ¼ 21.4 Hz), 63.0, 48.1, 42.0, 38.8, 30.8, 24.4, 24.0, 21.1, 20.9, 20.6,
18.6, 14.0; IR (ATR, neat): n 2957, 2925, 2858, 1642, 1626, 1603, 1507,
1466, 1459, 1447, 1367, 1343, 1279, 1220, 1157, 1146, 1078, 858, 830,
817, 787, 759 cm1; HRMS (ESI, [MþH]þ) for C27H36FN2Oþ calcd.
423.2806, found 423.2819.
4.8. General procedure for PMB-deprotection of 1,3-
benzodiazepines 9f,e23
1,3-Benzodiazepine 9f (92 mg, 0.2 mmol) was placed in a screw
cap vial followed by addition of DCM (1.5 mL), triﬂuoroacetic acid
(0.5 mL) and triﬂic acid (12 mL). The resulting mixture was sealed
and stirred at 50 C for 3 h. Upon completion of this time, the
mixture was diluted with ethyl acetate and transferred to the round
bottom ﬂask. Then the silicagel was added and the mixture was
concentrated under reduced pressure. Column chromatography on
silica gel using petroleum ether-ethyl acetate (1:1) mixture as
eluent provided 1,3-benzodiazepine 20. Starting from 9e (45 mg,
0.1 mmol), 1,3-benzodiazepine 21was obtained following the same
procedure and using petroleum ether-ethyl acetate (9:1 / 8:2)
mixture as eluent for column chromatography.
4.8.1. (Z)-4-Benzyl-5-benzylidene-1,3,4,5-tetrahydro-2H-benzo[d]
[1,3]diazepin-2-one (20)
Yield: 90%; white solid; mp: 154e155 C; 1H NMR (400 MHz,
DMSO-d6): d 9.10 (bd, J ¼ 1.5 Hz, 1H), 7.58 (dd, J ¼ 7.2, 1.7 Hz, 1H),
7.37e7.14 (m, 9H), 7.14e7.08 (m, 2H), 7.02e6.94 (m, 1H), 6.93e6.85
(m, 2H), 6.73 (m, 1H), 4.52 (q, J ¼ 7.4 Hz, 1H), 2.76 (dd, J ¼ 13.4,
7.3 Hz, 1H), 2.64 (dd, J ¼ 13.4, 7.8 Hz, 1H); 13C NMR (100 MHz,
DMSO-d6): d 155.4, 139.4, 137.9, 137.4, 136.6, 129.8, 129.0, 128.8,
128.6, 128.3, 128.2, 127.8, 127.1, 126.3, 126.2, 121.3, 118.1, 50.0, 40.3;
IR (ATR, neat): n 3215, 3027, 1683, 1480, 1421, 1231, 746, 697 cm1;




Yield: 43%; beige solid; mp: 179e180 C; 1H NMR (400 MHz,
DMSO-d6): d 7.79e7.73 (m, 1H), 7.68 (bs, 1H), 7.52e7.36 (m, 7H),
7.29e7.17 (m, 3H), 7.16e7.06 (m, 4H), 4.06e4.00 (m, 2H), 13C NMR
(100 MHz, DMSO-d6) d 152.5, 140.7, 135.92, 135.85, 131.9, 129.2,
128.32, 128.28, 128.24, 128.0, 127.9, 125.9, 123.3, 121.1, 119.3, 115.5,
112.6, 29.6; IR (ATR, neat): n 3464, 3291, 3178, 2921, 1678, 1604,
1452, 1388, 1338, 740, 698 cm1; HRMS (ESI, [MþH]þ) for
C22H19N2Oþ calcd. 327.1492, found 327.1479.
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